scholarly journals Targeting EBV-positive B- and T/NK-cell lymphomas

Blood ◽  
2018 ◽  
Vol 132 (22) ◽  
pp. 2315-2316
Author(s):  
Heather M. Long

In this issue of Blood, McLaughlin et al demonstrate the safety and efficacy of donor-derived Epstein-Barr virus (EBV) latent membrane protein (LMP)-specific T cells to prevent relapse of aggressive EBV-positive B- or T/NK-cell lymphomas following allogeneic hematopoietic stem cell transplantation (HSCT).1

Sign in / Sign up

Export Citation Format

Share Document